• Lymphoma | What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

  • 2024/11/08
  • 再生時間： 56 分
  • ポッドキャスト

Lymphoma | What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Featuring an interview with Dr Gilles Salles, including the following topics:

    • Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
    • Natural history of FL and current treatment landscape in the first-line setting (5:20)
    • Testing approaches for the detection of EZH2 mutations (14:37)
    • Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
    • Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
    • Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
    • Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
    • Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
    • Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
    • Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
    • Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
    • Perspectives on the future treatment landscape of FL (54:29)

    CME information and select publications
    続きを読む 一部表示

あらすじ・解説

Featuring an interview with Dr Gilles Salles, including the following topics:

  • Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
  • Natural history of FL and current treatment landscape in the first-line setting (5:20)
  • Testing approaches for the detection of EZH2 mutations (14:37)
  • Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
  • Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
  • Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
  • Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
  • Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
  • Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
  • Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
  • Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
  • Perspectives on the future treatment landscape of FL (54:29)

CME information and select publications
続きを読む 一部表示

Lymphoma | What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphomaに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。